CIK 0000872589 · Large accelerated filer
REGENERON PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- REGN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- NY
- Entity type
- operating
- EIN
- 133444607
- Phone
- 9148477000
- Business address
- 777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY, 10591
- Former names
- REGENERON PHARMACEUTICALS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $51,901,544
- in 11 filings, $8.6M under 10b5-1 plans
Net −$51,901,544. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-01-02 | SING GEORGE L Director | Grant or award | +135 | 26,349 | ||
| 2024-01-02 | SING GEORGE L Director | Grant or award · Non-Qualified Stock Option (right to buy) | +1,607 | 1,607 | ||
| 2024-01-02 | GOLDSTEIN JOSEPH L Director | Grant or award | +135 | 6,382 | ||
| 2024-01-02 | GOLDSTEIN JOSEPH L Director | Grant or award · Non-Qualified Stock Option (right to buy) | +1,607 | 1,607 | ||
| 2024-01-02 | BROWN MICHAEL S Director | Grant or award | +135 | 1,382 | ||
| 2024-01-02 | BROWN MICHAEL S Director | Grant or award · Non-Qualified Stock Option (right to buy) | +1,607 | 1,607 | ||
| 2024-01-02 | YANCOPOULOS GEORGE Bd. Co-Chair, President & CSO | Sale 10b5-1 | −16,848 | $900.00 | $15.2M | 180,000 |
| 2024-01-02 | Landry Robert E EVP Finance CFO | Option exercise | +650 | $378.98 | $246K | 22,457 |
| 2024-01-02 | Landry Robert E EVP Finance CFO | Shares withheld for taxes | −421 | $888.34 | $374K | 22,036 |
| 2024-01-02 | Landry Robert E EVP Finance CFO | Option exercise · Non-Qualified Stock Option (right to buy) | −650 | 17,087 | ||
| 2024-01-02 | McCourt Marion EVP Commercial | Sale 10b5-1 | −274 | $873.91 | $239K | 15,062 |
| 2024-01-02 | Schenkein David P Director | Grant or award | +42 | 282 | ||
| 2024-01-02 | Schenkein David P Director | Grant or award · Non-Qualified Stock Option (right to buy) | +508 | 508 | ||
| 2024-01-02 | Guarini Kathryn Director | Grant or award | +42 | 282 | ||
| 2024-01-02 | Guarini Kathryn Director | Grant or award · Non-Qualified Stock Option (right to buy) | +508 | 508 | ||
| 2024-01-02 | Thompson Craig B. Director | Grant or award | +135 | 454 | ||
| 2024-01-02 | Thompson Craig B. Director | Grant or award · Non-Qualified Stock Option (right to buy) | +1,607 | 1,607 | ||
| 2023-12-28 | Landry Robert E EVP Finance CFO | Option exercise | +850 | $378.98 | $322K | 22,419 |
| 2023-12-28 | Landry Robert E EVP Finance CFO | Shares withheld for taxes | −612 | $884.88 | $542K | 21,807 |
| 2023-12-28 | Landry Robert E EVP Finance CFO | Option exercise · Non-Qualified Stock Option (right to buy) | −850 | 17,737 |
Page 42 of 49 · 971 trades